Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-12-10
1996-01-23
Stone, Jacqueline M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514 49, A01N 4354, A61K 31505
Patent
active
054865204
ABSTRACT:
The present invention relates to the use of nucleoside analogues in the treatment of viral infections. More specifically it is concerned with the use of 1,3-oxathiolane nucleoside analogues in the treatment of hepatitis, in particular hepatitis B.
REFERENCES:
patent: 5039667 (1991-08-01), Tyrell et al.
patent: 5047407 (1991-09-01), Belleau et al.
patent: 5151426 (1992-09-01), Belleau et al.
patent: 5204466 (1993-04-01), Liotta et al.
patent: 5210085 (1993-05-01), Liotta et al.
Coates et al., "The Separated Enantiomers of 2'-Deoxy-3'-Thiacytidine (BCH 189) Both Inhibit Human Immunodeficiency Virus Replication in Vitro," 36 Antimicrobial Agents & Chemotherapy, No. 1, pp. 202-205 (1992).
Doong et al., "Inhibition of the Replication of Hepatitis B Virus In-Vitro By 2'3' Dideoxy-3'-thiacytidine and Related Analogues," Thirty-first Annual Interscience Conference of Antimicrobial Agents and Chemotherapy, Chicago, Ill., USA, 29 Sep.-2 Oct. 1991, Program Abstract 31(0) 181 (1991).
Doong et al., "Inhibition of the Replication of Hepatitis B Virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues," 88 Proc. Natl. Acad. Sci., USA, pp. 8495-8499; 88 Physiology/Pharmacolgy 8495-99 (1991).
Greenberg et al., "Metabolism, Toxicity, and Anti-HIV Activity of 2'-Deoxy-3'-Thia-Cytidine (BCH-189) in T and B Cell Lines," 616 Annals of the New York Academy Of Sciences 517-18 (1990).
Kassianides et al. Abstract: "Effects of 2',3'-dideoxycytidine on Duck Hepatitis B Virus," 94 Gastroenterology No. 5, A552 (1988).
Kassianides et al., "Inhibition of Duck Hepatitis B Virus Replication by 2',3'-Dideoxycytidine," 97 Gastroenterology, No. 5, 1275-80 (1989).
Lee et al., "In Vitro and In Vivo Comparisons of the Abilities of Purine and Pyrimidine 2',3'-Dideoxynucleosides To Inhibit Duck Hepadnavirus," 33 Antimicrobial Agents and Chemotherapy, No. 3, 336-39 (1989).
Sandstrom et al., "Antiviral Therapy in AIDS: Clinical Pharmacological Properties and Therapeutic Experience to Date," 34 Drugs, pp. 372-390 (1987).
Soudeyns et al., "Anti-Human Immunodeficiency Virus Type 1 Activity and in Vitro Toxicity of 2'-Deoxy-3'-Thiacytidine (BCH-189), a Novel Heterocyclic Nucleoside Analog," 35 Antimicrobial Agents and Chemotherapy, No. 7, pp. 1386-1390 (1991).
Suzuki et al., "Inhibition of Hepatitis B Virus Replication By Purine 2',3'-Dideoxynucleosides," 156 Biochemical and Biophysical Research Communications 1144-51 (1988).
Varmus, "A Growing Role For Reverse Transcription," 299 Nature, pp. 204-205 (1982).
Wainberg et al., Abstract, "Anti-HIV-1 Activity, Toxicity And Pharmacokinetics of Totally Novel Nucleoside Analogs," M.C.P.63, V International Conference on AIDS, Montreal, Quebec, Canada, Jun. 4-9, 1989.
Wainberg et al., "Characterization Of AZT-Resistant Isolates Of HIV-1: Susceptibility To Deoxythiacytidine And Other Nucleosides," VI International Conference On AIDS, San Francisco, Calif., vol. 3, Abstract S.B.87, p. 117 (1990).
Beach et al., "Synthesis of Enantiomerically Pure (2'R,5'S)-(-)-1-[2-(Hydroxymethyl) oxathiolan-5-yl]cytosine as a Potent Antiviral Agent Against Hepatitis B Virus (HBV) And Human Immunodeficiency Virus (HIV)," 57 J. Org. Chem., pp. 2217-2219 (1992).
Belleau et al., "Design And Activity Of A Novel Class Of Nucleoside Analogs Effective Against HIV-1," Fifth International Conference On AIDS, Montreal, Canada, Abstract T.C.O.1 (1989).
Carlisle et al., "Cellular Pharmacology Of The Anti-HIV Agent BCH-189 (2'-Deoxy-3'-Thiacytidine) In Human Peripheral Blood Mononuclear Cells (PBMC)", American Association For Cancer Research Proceedings, 31 Abstract 2435 (1990).
Chang et al., "Deoxycytidine Deaminase-resistant Stereoisomer Is the Active Form of (.+-.)-2',-3'-Diedeoxy-3'-thiacytidine in the Inhibition of the Hepatitis B Virus Replication," 267 J. Biol. Chem., pp. 3938-3942 (1992).
Belleau, deceased Bernard
Nguyen-Ba Nghe
BioChemPharma, Inc.
Campbell Bruce R.
Flattmann, Jr. Gerald J.
McDonnell Leslie A.
Stone Jacqueline M.
LandOfFree
1,3-oxathiolanes useful in the treatment of hepatitis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1,3-oxathiolanes useful in the treatment of hepatitis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1,3-oxathiolanes useful in the treatment of hepatitis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1505164